BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36084875)

  • 1. Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer.
    Lin Q; Shen S; Qian Z; Rasam SS; Serratore A; Jusko WJ; Kandel ES; Qu J; Straubinger RM
    Mol Cell Proteomics; 2022 Oct; 21(10):100409. PubMed ID: 36084875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation.
    Lin Q; Qian Z; Jusko WJ; Mager DE; Ma WW; Straubinger RM
    J Pharmacol Exp Ther; 2021 Jun; 377(3):370-384. PubMed ID: 33753538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism.
    Fujiwara-Tani R; Sasaki T; Takagi T; Mori S; Kishi S; Nishiguchi Y; Ohmori H; Fujii K; Kuniyasu H
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
    Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
    Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single-agent fibroblast growth factor receptor-specific inhibitors in pancreatic cancer.
    Lin Q; Serratore A; Perri J; Roy Chaudhuri T; Qu J; Ma WW; Kandel ES; Straubinger RM
    Br J Pharmacol; 2024 May; 181(9):1383-1403. PubMed ID: 37994108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquisition of gemcitabine resistance enhances angiogenesis via upregulation of IL‑8 production in pancreatic cancer.
    Imafuji H; Matsuo Y; Ueda G; Omi K; Hayashi Y; Saito K; Tsuboi K; Morimoto M; Koide S; Ogawa R; Hara M; Takahashi H; Takiguchi S
    Oncol Rep; 2019 Jun; 41(6):3508-3516. PubMed ID: 31002348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma.
    Miller AL; Garcia PL; Gamblin TL; Vance RB; Yoon KJ
    Cancer Drug Resist; 2020; 3(3):572-585. PubMed ID: 33073205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer.
    Park JM; Peng JM; Shen YS; Lin CY; Hsu TW; Su YH; Chen HA; Saengboonmee C; Chang JS; Chiu CF; Shan YS
    Mol Metab; 2022 Nov; 65():101576. PubMed ID: 35995401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of integrin‑linked kinase enhances tumor progression in gemcitabine‑resistant pancreatic cancer.
    Murase H; Matsuo Y; Denda Y; Nonoyama K; Kato T; Aoyama Y; Hayashi Y; Imafuji H; Saito K; Morimoto M; Ogawa R; Takahashi H; Mitsui A; Kimura M; Takiguchi S
    Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37477162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic analysis of gemcitabine-induced drug resistance in pancreatic cancer cells.
    Chen YW; Liu JY; Lin ST; Li JM; Huang SH; Chen JY; Wu JY; Kuo CC; Wu CL; Lu YC; Chen YH; Fan CY; Huang PC; Law CH; Lyu PC; Chou HC; Chan HL
    Mol Biosyst; 2011 Nov; 7(11):3065-74. PubMed ID: 21894339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer.
    Ma G; Sun Y; Fu S
    Int J Clin Exp Pathol; 2015; 8(10):13284-8. PubMed ID: 26722531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pterostilbene Enhances Cytotoxicity and Chemosensitivity in Human Pancreatic Cancer Cells.
    Hsu YH; Chen SY; Wang SY; Lin JA; Yen GC
    Biomolecules; 2020 May; 10(5):. PubMed ID: 32375296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones.
    Yoneyama H; Takizawa-Hashimoto A; Takeuchi O; Watanabe Y; Atsuda K; Asanuma F; Yamada Y; Suzuki Y
    Anticancer Drugs; 2015 Jan; 26(1):90-100. PubMed ID: 25187316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.
    Duong HQ; Hwang JS; Kim HJ; Kang HJ; Seong YS; Bae I
    Int J Oncol; 2012 Sep; 41(3):855-61. PubMed ID: 22710732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
    Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
    Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursolic acid promotes apoptosis, autophagy, and chemosensitivity in gemcitabine-resistant human pancreatic cancer cells.
    Lin JH; Chen SY; Lu CC; Lin JA; Yen GC
    Phytother Res; 2020 Aug; 34(8):2053-2066. PubMed ID: 32185829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness.
    Lin Q; Serratore A; Niu J; Shen S; Roy Chaudhuri T; Ma WW; Qu J; Kandel ES; Straubinger RM
    Drug Resist Updat; 2024 Mar; 73():101064. PubMed ID: 38387284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Wu L; Ge Y; Yuan Y; Li H; Sun H; Xu C; Wang Y; Zhao T; Wang X; Liu J; Gao S; Chang A; Hao J; Huang C
    Cancer Lett; 2022 Nov; 548():215864. PubMed ID: 35981571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.